目的 探讨博尔宁胶囊联合表阿霉素和紫杉醇治疗乳腺癌的临床疗效。方法 选取2017年2月-2018年1月在新疆生产建设兵团第九师医院治疗的乳腺癌患者76例，根据用药的差别分为对照组（38例）和治疗组（38例）。对照组静脉滴注紫杉醇注射液，175 mg/m²加入5%葡萄糖注射液500 mL，1次/d，同时肌肉注射注射用盐酸表阿霉素，60 mg/m²，1次/d。治疗组在对照组基础上口服博尔宁胶囊，4粒/次，3次/d。两组均治疗6周。观察两组患者临床疗效，同时比较治疗前后两组患者肿瘤标志物、促血管生长因子水平和QLQ-C30评分。结果 治疗后，对照组客观缓解率（ORR）和临床获益率（CBR）分别为47.37%和55.26%，均显著低于治疗组的63.16%和76.32%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清癌胚抗原（CEA）、糖抗原125（CA125）、糖抗原153（CA153）、恶性肿瘤生长因子（TSGF）水平均显著降低（P<0.05），且治疗组患者上述肿瘤标志物水平明显低于对照组（P<0.05）。治疗后，两组患者血清细胞间黏附分子-1（ICAM-1）、缺氧诱导因子-1α（HIF-1α）、血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）水平均显著降低（P<0.05），且治疗后治疗组促血管生长因子水平明显低于对照组（P<0.05）。治疗后，两组患者QLQ-C30量表各项目评分均明相升高（P<0.05），且治疗组QLQ-C30评分明显高于对照组（P<0.05）。结论 博尔宁胶囊联合表阿霉素和紫杉醇治疗乳腺癌可有效抑制肿瘤新生血管生成，有利于提高患者生活质量，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Boerning Capsules combined with epirubicin and paclitaxel in treatment of breast cancer. Methods Patients (76 cases) with breast cancer in Xinjiang Production and Construction 9 Agriculture Division of Corps Hospital from February 2017 to January 2018 were divided into control (38 cases) and treatment (38 cases) groups bases on different treatments. Patients in the control group were iv administered with Paclitaxel Injection, 175 mg/m² added into 5% Glucose Injection 500 mL, once daily, and at the same time they were intramuscular injection administered with Epirubicin Hydrochloride for injection, 60 mg/m², once daily. Patients in the treatment group were po administered with Boerning Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the tumor markers, angiogenic growth factors levels, and QLQ-C30 scores in two groups before and after treatment were compared. Results After treatment, the objective reaction rate (ORR) and clinical benefit rate (CBR) in the control group were 47.37% and 55.26%, which were significantly lower than 63.16% and 76.32% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the CEA, CA125, CA153, and TSGF levels in two groups were significantly decreased (P<0.05), and these tumor markers levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the ICAM-1, HIF-1α, VEGF, and bFGF levels in two groups were significantly decreased (P<0.05), and the angiogenic growth factors levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the QLQ-C30 scores in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Boerning Capsules combined with epirubicin and paclitaxel in treatment of breast cancer can effectively inhibit the formation of neovascularization of the tumor, and improve the quality of life, which has a certain clinical application value.